Additional file 1: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Additional file 1: of Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma

Licun Wu (522271)
Walter Blum (4167670)
Chang-Qi Zhu (129006)
Zhihong Yun (5148503)
Laszlo Pecze (3603545)
Mikihiro Kohno (5148506)
Mei-Lin Chan (3992849)
Yidan Zhao (522267)
Emanuela Felley-Bosco (82830)
Beat Schwaller (86027)
Marc de Perrot (522275)

April 2018

Figure S1. Expression of CSC-associated genes up-regulated in AB12 and RN5 cells after cisplatin tre...

Additional file 1: of Correlate tumor mutation burden with immune signatures in human cancers

Xiaosheng Wang (553236)
Mengyuan Li (415985)

January 2019

Table S1. Comparison of regulatory T cell marker genes expression levels between the lower-TMB and t...

Additional file 1: of Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Francesca Finotello (5803820)
Clemens Mayer (6737843)
Christina Plattner (6737846)
Gerhard Laschober (6737849)
Dietmar Rieder (3631147)
Hubert Hackl (15768)
Anne Krogsdam (2559910)
Zuzana Loncova (6737852)
Wilfried Posch (249579)
Doris Wilflingseder (249602)
Sieghart Sopper (823900)
Marieke Ijsselsteijn (6737855)
Thomas Brouwer (6689672)
Douglas Johnson (302588)
Yaomin Xu (221417)
Yu Wang (12152)
Melinda Sanders (6737858)
Monica Estrada (219127)
Paula Ericsson-Gonzalez (6737861)
Pornpimol Charoentong (849763)
Justin Balko (4424944)
Noel Filipe da Cunha Carvahlo de Miranda (6737864)
Zlatko Trajanoski (15774)

May 2019

quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...

Additional file 4: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S1. Genomic features of patients with GC who received RAM-containing therapies. (DOCX 137 kb

Additional file 9: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S6. Kinetic changes of IC molecule expression by CD45RAâFOXP3âCD4+ T cells in both PBMCs ...

Additional file 8: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S5. Kinetic changes of IC molecule expression by CD8+ T cells in both PBMCs and TILs. (DOCX 2...

Additional file 11: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S8. Comparison of IC expression by eTreg cells between pre-and post-treatment in both PBMCs a...

Additional file 7: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S4. Kinetic changes of CD45RAâFOXP3âCD4+ T cells and eTreg cells in CD3+ T cells. (DOCX 1...

Additional file 12: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S9. % of eTreg-cell reduction and % of PD-1 reduction on CD8+ T cells and clinical responses....

Additional file 6: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S3. Kinetic changes of eTreg cells and PD-1 expression by CD8+ T cells according to therapies...

Additional file 10: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S7. Kinetic changes of IC molecule expression by eTreg cells in both PBMCs and TILs. (DOCX 10...

Additional file 5: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S2. Difference in patient characteristics according to eTreg-cell frequency in TIL. (DOCX 129...

Additional file 1: of Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma

Young Kim (4006)
Kyung Kim (31555)
Ghee-Young Kwon (5577032)
Su Lee (3454505)
Se Park (5577035)

July 2018

Table S1. List of targeted genes in Ion AmpliSeqâ˘ Cancer Panel v2. (XLSX 79 kb

Additional file 5: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa Carnevalli (179142)
Charles Sinclair (6158843)
Molly Taylor (6158846)
Pablo Gutierrez (6158849)
Sophie Langdon (6158852)
Anna Coenen-Stass (1571842)
Lorraine Mooney (372137)
Adina Hughes (6158855)
Laura Jarvis (6158858)
Anna Staniszewska (5892953)
Claire Crafter (1981513)
Ben Sidders (35030)
Elizabeth Hardaker (6158861)
Kevin Hudson (1629772)
Simon Barry (255454)

December 2018

Table S2. List of differentiated expressed genes in control and AZD8835 treated tumors at day 7 and ...

Additional file 1: of VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer

Lian Lian (5046749)
Xiang-Li Li (6413219)
Meng-Dan Xu (6413222)
Xian-Min Li (6413225)
Meng-Yao Wu (6413228)
Yan Zhang (8098)
Min Tao (143985)
Wei Li (7081)
Xiao-Ming Shen (6413231)
Chong Zhou (6413234)
Min Jiang (56794)

March 2019

The data of microarray analysis of VEGFR2 signaling in gastric cancer cells. (XLSX 18770 kb

Additional file 1: of Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma

Licun Wu (522271)
Walter Blum (4167670)
Chang-Qi Zhu (129006)
Zhihong Yun (5148503)
Laszlo Pecze (3603545)
Mikihiro Kohno (5148506)
Mei-Lin Chan (3992849)
Yidan Zhao (522267)
Emanuela Felley-Bosco (82830)
Beat Schwaller (86027)
Marc de Perrot (522275)

April 2018

Figure S1. Expression of CSC-associated genes up-regulated in AB12 and RN5 cells after cisplatin tre...

Additional file 1: of Correlate tumor mutation burden with immune signatures in human cancers

Xiaosheng Wang (553236)
Mengyuan Li (415985)

January 2019

Table S1. Comparison of regulatory T cell marker genes expression levels between the lower-TMB and t...

Additional file 1: of Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Francesca Finotello (5803820)
Clemens Mayer (6737843)
Christina Plattner (6737846)
Gerhard Laschober (6737849)
Dietmar Rieder (3631147)
Hubert Hackl (15768)
Anne Krogsdam (2559910)
Zuzana Loncova (6737852)
Wilfried Posch (249579)
Doris Wilflingseder (249602)
Sieghart Sopper (823900)
Marieke Ijsselsteijn (6737855)
Thomas Brouwer (6689672)
Douglas Johnson (302588)
Yaomin Xu (221417)
Yu Wang (12152)
Melinda Sanders (6737858)
Monica Estrada (219127)
Paula Ericsson-Gonzalez (6737861)
Pornpimol Charoentong (849763)
Justin Balko (4424944)
Noel Filipe da Cunha Carvahlo de Miranda (6737864)
Zlatko Trajanoski (15774)

May 2019

quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...

Additional file 4: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S1. Genomic features of patients with GC who received RAM-containing therapies. (DOCX 137 kb

Additional file 9: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S6. Kinetic changes of IC molecule expression by CD45RAâFOXP3âCD4+ T cells in both PBMCs ...

Additional file 8: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S5. Kinetic changes of IC molecule expression by CD8+ T cells in both PBMCs and TILs. (DOCX 2...

Additional file 11: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S8. Comparison of IC expression by eTreg cells between pre-and post-treatment in both PBMCs a...

Additional file 7: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S4. Kinetic changes of CD45RAâFOXP3âCD4+ T cells and eTreg cells in CD3+ T cells. (DOCX 1...

Additional file 12: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S9. % of eTreg-cell reduction and % of PD-1 reduction on CD8+ T cells and clinical responses....

Additional file 6: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S3. Kinetic changes of eTreg cells and PD-1 expression by CD8+ T cells according to therapies...

Additional file 10: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S7. Kinetic changes of IC molecule expression by eTreg cells in both PBMCs and TILs. (DOCX 10...

Additional file 5: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada (5852297)
Yosuke Togashi (550136)
Daisuke Kotani (5852306)
Takeshi Kuwata (282000)
Eichi Sato (5852309)
Akihito Kawazoe (5852312)
Toshihiko Doi (616029)
Hisashi Wada (5852315)
Hiroyoshi Nishikawa (2938410)
Kohei Shitara (5852318)

October 2018

Figure S2. Difference in patient characteristics according to eTreg-cell frequency in TIL. (DOCX 129...

Additional file 1: of Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma

Young Kim (4006)
Kyung Kim (31555)
Ghee-Young Kwon (5577032)
Su Lee (3454505)
Se Park (5577035)

July 2018

Table S1. List of targeted genes in Ion AmpliSeqâ˘ Cancer Panel v2. (XLSX 79 kb

Additional file 5: of PI3KÎą/Î´ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Larissa Carnevalli (179142)
Charles Sinclair (6158843)
Molly Taylor (6158846)
Pablo Gutierrez (6158849)
Sophie Langdon (6158852)
Anna Coenen-Stass (1571842)
Lorraine Mooney (372137)
Adina Hughes (6158855)
Laura Jarvis (6158858)
Anna Staniszewska (5892953)
Claire Crafter (1981513)
Ben Sidders (35030)
Elizabeth Hardaker (6158861)
Kevin Hudson (1629772)
Simon Barry (255454)

December 2018

Table S2. List of differentiated expressed genes in control and AZD8835 treated tumors at day 7 and ...

Additional file 1: of VEGFR2 promotes tumorigenesis and metastasis in a pro-angiogenic-independent way in gastric cancer

Lian Lian (5046749)
Xiang-Li Li (6413219)
Meng-Dan Xu (6413222)
Xian-Min Li (6413225)
Meng-Yao Wu (6413228)
Yan Zhang (8098)
Min Tao (143985)
Wei Li (7081)
Xiao-Ming Shen (6413231)
Chong Zhou (6413234)
Min Jiang (56794)

March 2019

The data of microarray analysis of VEGFR2 signaling in gastric cancer cells. (XLSX 18770 kb

Additional file 1: of Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma

Licun Wu (522271)
Walter Blum (4167670)
Chang-Qi Zhu (129006)
Zhihong Yun (5148503)
Laszlo Pecze (3603545)
Mikihiro Kohno (5148506)
Mei-Lin Chan (3992849)
Yidan Zhao (522267)
Emanuela Felley-Bosco (82830)
Beat Schwaller (86027)
Marc de Perrot (522275)

April 2018

Figure S1. Expression of CSC-associated genes up-regulated in AB12 and RN5 cells after cisplatin tre...

Additional file 1: of Correlate tumor mutation burden with immune signatures in human cancers

Xiaosheng Wang (553236)
Mengyuan Li (415985)

January 2019

Table S1. Comparison of regulatory T cell marker genes expression levels between the lower-TMB and t...

Additional file 1: of Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data

Francesca Finotello (5803820)
Clemens Mayer (6737843)
Christina Plattner (6737846)
Gerhard Laschober (6737849)
Dietmar Rieder (3631147)
Hubert Hackl (15768)
Anne Krogsdam (2559910)
Zuzana Loncova (6737852)
Wilfried Posch (249579)
Doris Wilflingseder (249602)
Sieghart Sopper (823900)
Marieke Ijsselsteijn (6737855)
Thomas Brouwer (6689672)
Douglas Johnson (302588)
Yaomin Xu (221417)
Yu Wang (12152)
Melinda Sanders (6737858)
Monica Estrada (219127)
Paula Ericsson-Gonzalez (6737861)
Pornpimol Charoentong (849763)
Justin Balko (4424944)
Noel Filipe da Cunha Carvahlo de Miranda (6737864)
Zlatko Trajanoski (15774)

May 2019

quanTIseq signature matrix and used RNA-seq data from purified/enriched immune cells. RNA-seq data: ...

Additional file 1: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Abstract

Extracted data

Additional file 1: of Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Abstract

Extracted data

Related items

Related items